Medical Breakthrough And Preventive Health
From WikiDemocracy
FDA approves first-ever gene therapy for genetic hearing loss
U.S. Food and Drug Administration. FDA. April 23, 2026.
Summary: The FDA approved Otarmeni, a dual AAV vector-based gene therapy for severe-to-profound hearing loss caused by confirmed biallelic OTOF gene variants. The approval is a major genetic-medicine milestone because it targets a specific inherited cause of deafness rather than treating hearing loss only with external devices.
FDA approves gene therapy for spinal muscular atrophy
U.S. Food and Drug Administration. FDA. November 24, 2025.
Summary: The FDA approved Itvisma, an AAV vector-based gene therapy for spinal muscular atrophy in adults and children age 2 and older with confirmed SMN1 mutation. The treatment adds another gene-therapy option for a serious inherited neuromuscular disease that can cause progressive weakness and disability.
FDA approves first immunotherapy for recurrent respiratory papillomatosis
U.S. Food and Drug Administration. FDA. August 14, 2025.
Summary: The FDA approved Papzimeos, the first immunotherapy for adults with recurrent respiratory papillomatosis, a rare disease usually caused by HPV types 6 or 11. The approval is important because patients can require repeated surgeries to keep the airway open, and a disease-modifying immunotherapy may reduce that burden.
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma
U.S. Food and Drug Administration. FDA. November 25, 2025.
Summary: The FDA approved durvalumab with FLOT chemotherapy before and after surgery for adults with resectable gastric or gastroesophageal junction adenocarcinoma, followed by durvalumab alone. The decision reflects the expansion of immunotherapy into earlier cancer treatment, where the goal is to prevent relapse after potentially curative surgery.
FDA approves pembrolizumab with enfortumab vedotin for muscle invasive bladder cancer
U.S. Food and Drug Administration. FDA. November 21, 2025.
Summary: The FDA approved pembrolizumab with enfortumab vedotin before surgery and afterward for adults with muscle-invasive bladder cancer who are ineligible for cisplatin. The combination pairs immunotherapy with an antibody-drug conjugate, extending a powerful metastatic-cancer strategy into earlier-stage disease.
FDA grants accelerated approval to sevabertinib for HER2-mutated non-small cell lung cancer
U.S. Food and Drug Administration. FDA. November 19, 2025.
Summary: The FDA granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2, or ERBB2, tyrosine kinase domain activating mutations after prior systemic therapy. The approval shows the growing importance of matching lung-cancer treatment to specific tumor mutations.
FDA grants traditional approval to tarlatamab for extensive-stage small cell lung cancer
U.S. Food and Drug Administration. FDA. November 19, 2025.
Summary: The FDA granted traditional approval to tarlatamab for adults with extensive-stage small cell lung cancer whose disease progressed after platinum-based chemotherapy. Tarlatamab is a bispecific T-cell engager, part of a broader wave of immune-directed cancer therapies that recruit the patient’s immune cells to attack tumors.
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia
U.S. Food and Drug Administration. FDA. November 13, 2025.
Summary: The FDA approved ziftomenib for adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation and no satisfactory alternative treatment options. The drug is a menin inhibitor, showing how leukemia care is increasingly being divided by the molecular drivers of the disease.
FDA approves daratumumab for high-risk smoldering multiple myeloma
U.S. Food and Drug Administration. FDA. November 6, 2025.
Summary: The FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma. This is important because it treats a precursor condition before full multiple myeloma develops, fitting the larger trend toward cancer interception rather than waiting for advanced disease.
FDA approves revumenib for acute myeloid leukemia with NPM1 mutation
U.S. Food and Drug Administration. FDA. October 24, 2025.
Summary: The FDA approved revumenib for adults and children age 1 and older with relapsed or refractory acute myeloid leukemia carrying a susceptible NPM1 mutation. Like other menin inhibitors, revumenib is part of a precision-medicine shift in AML treatment based on genetic subtypes.
FDA approves nivolumab with ipilimumab for unresectable or metastatic liver cancer
U.S. Food and Drug Administration. FDA. April 11, 2025.
Summary: The FDA approved nivolumab with ipilimumab as first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma. The approval is relevant to both treatment and prevention because liver cancer is often linked to preventable or treatable causes, including hepatitis B, hepatitis C, alcohol-related liver disease, and fatty liver disease.
Researchers identify new blood markers that may detect early pancreatic cancer
National Institutes of Health. NIH. January 30, 2026.
Summary: NIH-funded researchers identified a four-marker blood panel that may help detect early pancreatic cancer. The work is still in development, but it is important because pancreatic cancer is often diagnosed late, and earlier detection could make surgery or other treatments possible for more patients.
United by Unique: reimagining future cancer care through precision prevention
J. Ngeow et al. National Library of Medicine / PMC. 2026.
Summary: This article argues that cancer care is shifting from late-stage treatment toward earlier interception, risk stratification, and prevention guided by each person’s biology. It is useful for explaining how genetics, biomarkers, screening, and prevention may increasingly merge into one personalized cancer-control strategy.
Accelerating discovery of cancer causes for prevention in the next era
Summary: This roadmap calls for stronger research into the causes of cancer so prevention can advance faster. It argues that better data, new methods, and broader collaboration are needed to identify environmental, infectious, genetic, metabolic, and social contributors to cancer risk.
World Immunization Week 2026 highlights vaccine-preventable cancers
International Agency for Research on Cancer. IARC. April 28, 2026.
Summary: IARC marked World Immunization Week 2026 by noting that more than 1.1 million cancer cases in 2020 were caused by vaccine-preventable infections. The article reinforces the importance of HPV and hepatitis B vaccination as cancer-prevention tools, not just infectious-disease interventions.
Vaccination policies and the impact on the cancer community
American Cancer Society Cancer Action Network. ACS CAN. March 30, 2026.
Summary: ACS CAN explains how childhood vaccination helps prevent cancers caused by HPV and hepatitis B. The article emphasizes that strong vaccine policy, public trust, and access are essential parts of cancer prevention, especially when misinformation or barriers reduce immunization coverage.
World Malaria Day 2026: malaria ends with us
World Health Organization. WHO. April 25, 2026.
Summary: WHO’s World Malaria Day 2026 campaign highlighted malaria vaccines, new-generation insecticide-treated nets, seasonal chemoprevention, diagnosis, treatment, and community leadership. The article shows how malaria prevention now depends on a layered strategy rather than any single tool.
The Power of Science for Health: Malawi’s milestones transforming lives
WHO Regional Office for Africa. WHO Africa. June 8, 2026.
Summary: WHO Africa highlighted Malawi’s recent public-health achievements, including a nationwide polio vaccination campaign in March 2026 and evidence-based HIV prevention tools. The article is useful as a community-health example of how vaccination campaigns, science communication, and local delivery systems save lives.
When science informs health decisions: interview with Professor Alpha Kabinet Keita
WHO Regional Office for Africa. WHO Africa. April 10, 2026.
Summary: This WHO Africa interview describes how Ebola vaccines, improved surveillance, and digital health tools strengthened public-health response in Guinea and West Africa. It is relevant to preventative health because it shows how outbreak preparedness and trust in science can prevent local threats from becoming wider crises.
WHO launches implementation handbook to accelerate hepatitis elimination
World Health Organization. WHO. March 10, 2026.
Summary: WHO released consolidated guidance and an implementation handbook to help countries expand hepatitis B and C prevention, testing, treatment, service delivery, and program monitoring. Hepatitis elimination is a major cancer-prevention strategy because chronic hepatitis can lead to cirrhosis and liver cancer.
WHO Director-General’s remarks at the World TB Day Talk Show
World Health Organization. WHO. March 18, 2026.
Summary: WHO emphasized country-led tuberculosis action, better diagnosis, shorter treatment, and preparation for future TB vaccines through the TB Vaccine Accelerator. The article frames TB control as a prevention challenge that requires both new tools and strong health systems.
New TB vaccine research
World Health Organization. WHO. 2026.
Summary: WHO summarizes the expected value of new tuberculosis vaccines for health, productivity, equity, antibiotic stewardship, cost-effectiveness, and economic growth. The page is useful because TB vaccine development is one of the most important unfinished goals in infectious-disease prevention.
Women’s preferences for home-based self-sampling for cervical cancer screening
J. F. Domgue et al. National Library of Medicine / PMC. 2026.
Summary: This article reviews women’s preferences and barriers around home-based self-sampling for cervical-cancer screening. It is important because self-collection can reduce discomfort, embarrassment, travel barriers, and clinic-access problems that keep many people from completing HPV-based screening.
The power of movement: why physical activity remains a public-health priority
A. A. Owoeye et al. National Library of Medicine / PMC. March 13, 2026.
Summary: This review examines how social media, wearables, and mobile health platforms can influence physical activity behavior. It is useful for prevention because it asks how modern communication tools can support movement at scale, especially when inactivity remains a major risk factor for chronic disease.
How preventive medicine can bring a new era of longevity
World Economic Forum. World Economic Forum. January 2026.
Summary: This article describes how digital health, at-home diagnostics, wearable data, and personalized screening are reshaping preventive medicine. It is useful for tracking the shift from treating disease after symptoms appear toward earlier detection, risk management, and health-span extension.
Five key health and nutrition megatrends for 2026
Kerry Health and Nutrition Institute. KHNI. 2026.
Summary: This report identifies 2026 nutrition themes including gut health, women’s health, healthy aging, protein quality, and sustainable food systems. It is useful for following how nutrition research and public-health messaging are moving beyond simple calorie counting toward longer-term metabolic and whole-person health.
Healthy lifestyle habits for 2026
Washington University School of Medicine in St. Louis. Department of Surgery. December 29, 2025.
Summary: This guide highlights diet, physical activity, sleep, smoking cessation, preventive checkups, and mental health as practical habits for long-term health. It is a general but useful prevention article because it connects everyday behavior to chronic-disease risk reduction.
References on blood-based tests for multiple cancer screening
National Center for Biotechnology Information. NCBI Bookshelf. 2025.
Summary: This NCBI resource gathers references on blood-based multi-cancer screening tests, including clinical studies, cost-effectiveness analyses, patient preferences, and public perspectives. It is useful as a source trail for understanding both the promise and the unresolved evidence questions around multi-cancer blood tests.
Unlocking early cancer detection: exploring biomarkers in modern medicine
B. K. Prasanth et al. National Library of Medicine / PMC. 2023.
Summary: This review explains how biomarkers can help detect cancer earlier, assess risk, and monitor disease. It provides background for newer early-detection research by describing why blood, tissue, genetic, protein, and metabolic signals are central to modern cancer screening and diagnosis.
FDA approves first treatment for liver scarring due to fatty liver disease
U.S. Food and Drug Administration. FDA. March 14, 2024.
Summary: The FDA approved resmetirom, sold as Rezdiffra, for adults with noncirrhotic nonalcoholic steatohepatitis with moderate to advanced liver fibrosis, along with diet and exercise. The approval matters for preventive health because fatty liver disease can progress to cirrhosis, liver failure, and liver cancer if not addressed.
FDA approves neoadjuvant and adjuvant pembrolizumab for resectable head and neck cancer
U.S. Food and Drug Administration. FDA. June 12, 2025.
Summary: The FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1. The treatment can be given before surgery and continued afterward, showing how immunotherapy is moving earlier in cancer care where the goal is improving cure rates and reducing recurrence.
FDA approves mitomycin intravesical solution for recurrent low-grade bladder cancer
U.S. Food and Drug Administration. FDA. June 12, 2025.
Summary: The FDA approved mitomycin intravesical solution, sold as Zusduri, for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The treatment is delivered directly into the bladder, offering a localized option for a cancer that often recurs and requires repeated procedures.
FDA approves darolutamide for metastatic castration-sensitive prostate cancer
U.S. Food and Drug Administration. FDA. June 3, 2025.
Summary: The FDA approved darolutamide for metastatic castration-sensitive prostate cancer. This expands use of an androgen-receptor inhibitor in prostate cancer care and reflects the trend toward using more effective systemic therapy earlier in metastatic disease.
FDA grants accelerated approval to datopotamab deruxtecan for EGFR-mutated non-small cell lung cancer
U.S. Food and Drug Administration. FDA. June 23, 2025.
Summary: The FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer after prior EGFR-directed therapy and platinum chemotherapy. The antibody-drug conjugate approach delivers cancer-killing treatment more directly to tumor cells.
FDA approves imlunestrant for ER-positive, HER2-negative ESR1-mutated advanced breast cancer
U.S. Food and Drug Administration. FDA. September 25, 2025.
Summary: The FDA approved imlunestrant for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. The approval is important because ESR1 mutations can make standard hormone therapies less effective, and new estrogen-receptor drugs are designed to address that resistance.
FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor
U.S. Food and Drug Administration. FDA. February 14, 2025.
Summary: The FDA approved vimseltinib for adults with symptomatic tenosynovial giant cell tumor when surgery could cause severe morbidity or loss of function. Although this tumor is usually not life-threatening like many cancers, the approval matters because it gives patients a targeted option when surgery is risky.
AI screening tool gives pathologists “spatial super vision” to detect hidden cancer
QIMR Berghofer Medical Research Institute. Medical Xpress. May 6, 2026.
Summary: Researchers developed an AI tool that uses spatial biology patterns to help pathologists detect hidden genetic markers in standard tissue samples. The work suggests that future pathology may combine ordinary microscope slides with AI-enhanced molecular clues to guide more precise cancer diagnosis and treatment.
RNA molecule discovery could lead to potential new breast cancer therapy
QIMR Berghofer Medical Research Institute. Medical Xpress. February 3, 2026.
Summary: Scientists identified a cancer-fighting RNA molecule that may point toward a new RNA-based therapy for hormone receptor-positive breast cancer. The discovery is still early, but it shows how RNA biology is becoming important not only for vaccines, but also for targeted cancer treatment.
Surprising finding could pave way for universal cancer vaccine
University of Florida. Medical Xpress. July 18, 2025.
Summary: Researchers reported that an experimental mRNA vaccine boosted immunotherapy responses in mouse models by broadly activating the immune system against tumors. The work is preclinical, but it adds to a growing field of cancer-vaccine research aimed at making tumors more visible to immune attack.
Clinical trial of personalized cancer vaccine demonstrates early immune activity
University of Arizona Health Sciences. Medical Xpress. December 15, 2025.
Summary: Researchers reported early clinical results from a personalized cancer vaccine platform designed to train the immune system against patient-specific tumor targets. The article highlights the movement toward individualized immunotherapy, where cancer vaccines are tailored to the mutations or antigens present in a person’s tumor.
Emerging biomarkers for early cancer detection and diagnosis
S. Zafar et al. National Library of Medicine / PMC. 2025.
Summary: This review summarizes blood-based, molecular, imaging, and other biomarkers being investigated for earlier cancer detection. It is useful for understanding why a promising biomarker must be accurate, reproducible, affordable, and clinically meaningful before it can become part of routine screening.
Challenges in the future of cancer screening
E. Lynge. National Library of Medicine / PMC. 2025.
Summary: This review explores the tradeoffs that shape cancer screening, including false positives, overdiagnosis, screening intervals, risk-based screening, and evidence of mortality reduction. It is a good counterbalance to hype because it explains why finding more abnormalities is not always the same as saving more lives.
Transforming cancer screening: the potential of multi-cancer early detection
M. Imai et al. National Library of Medicine / PMC. 2025.
Summary: This article reviews multi-cancer early detection tests that use blood-based signals to look for several cancers at once. It explains the promise of earlier diagnosis for cancers without standard screening, while also stressing the need for evidence that such tests improve outcomes and do not create excessive harms.
Early detection of lung cancer: a review of innovative approaches
F. M. Habbab et al. National Library of Medicine / PMC. 2025.
Summary: This review covers low-dose CT screening, biomarkers, artificial intelligence, breath analysis, and other emerging tools for lung-cancer detection. It highlights the challenge of improving early diagnosis while reducing false positives, unnecessary procedures, and unequal access to screening.
Advances in pancreatic cancer early diagnosis, prevention, and treatment
A. Mannucci et al. National Library of Medicine / PMC. 2025.
Summary: This review examines progress in pancreatic-cancer risk assessment, molecular profiling, early diagnosis, and new treatment strategies. Pancreatic cancer remains one of the hardest cancers to catch early, making prevention, high-risk surveillance, and better biomarkers especially important.
Blood test enables earlier detection of heart and kidney damage
University of Sydney. Medical Xpress. May 12, 2026.
Summary: Researchers found that biochemical traces from the blood-vessel lining can appear on red blood cells, potentially creating a blood-test signal for earlier vascular damage. The discovery could one day help doctors detect risks to the heart, kidneys, and blood vessels before advanced disease develops.
AI uses sleep study data to predict dozens of future health issues
Reuters. Reuters. January 7, 2026.
Summary: Researchers reported that AI analysis of one night of sleep-lab brain recordings could help predict future risk for many health conditions. The study points toward a preventive-health future where existing clinical data may reveal patterns that identify people needing earlier monitoring.
Novel approach to HIV vaccine shows early promise
Reuters. Reuters. May 16, 2025.
Summary: Early human studies of a germline-targeting HIV vaccine strategy showed signs of activating rare immune cells needed to generate broadly neutralizing antibodies. The work is still preliminary, but it represents a major scientific route toward a preventive HIV vaccine.
Experimental flu drug with compound found in chocolate tops Tamiflu in early study
Reuters. Reuters. August 6, 2025.
Summary: Researchers reported early evidence that a flu-treatment strategy involving theobromine and a synthetic compound outperformed Tamiflu in preliminary studies. The finding is not yet a clinical breakthrough, but it shows how antiviral research continues to search for new mechanisms beyond existing flu drugs.
Mailing stool-test kits boosts colorectal cancer screening
Reuters. Reuters. August 6, 2025.
Summary: Research highlighted by Reuters found that mailing stool-test kits increased colorectal-cancer screening participation. This is a practical prevention success because reducing friction can help more people complete screening before colorectal cancer becomes advanced.
World Malaria Day 2026: malaria ends with us
World Health Organization. WHO. April 25, 2026.
Summary: WHO highlighted new malaria vaccines, improved mosquito nets, treatments, and emerging tools as part of the campaign to end malaria. The article frames malaria prevention as a combined effort involving immunization, vector control, diagnostics, treatment, community programs, and sustained national leadership.
Physical activity
World Health Organization. WHO. 2026.
Summary: WHO explains that physical activity includes movement during leisure, transport, work, and household tasks, and that both moderate and vigorous activity improve health. The page is a foundational reference for prevention because regular movement lowers risk for heart disease, diabetes, some cancers, depression, and premature death.
Vaccines and immunization
World Health Organization. WHO. 2026.
Summary: WHO summarizes the global role of vaccines in preventing more than 30 life-threatening diseases and helping people live longer, healthier lives. The page is useful for connecting individual vaccine breakthroughs to the broader public-health system that delivers protection across the lifespan.
WHO Director-General’s address to the 79th World Health Assembly
World Health Organization. WHO. May 19, 2026.
Summary: WHO’s Director-General highlighted progress and gaps in tuberculosis diagnosis, safer treatment regimens, malaria-vaccine rollout, and preparation for future TB vaccines. The speech is useful for tracking major global prevention priorities beyond cancer, including infectious diseases that still kill millions.
Prevention strategies
L. A. Kisling and J. M. Das. StatPearls / NCBI Bookshelf. Updated 2023.
Summary: This medical reference explains primary, secondary, and tertiary prevention, including vaccination, screening, risk-factor reduction, lifestyle counseling, and early disease detection. It provides a broad framework for organizing preventative-health topics across cancer, heart disease, infectious disease, diabetes, and community health.
Enhancing cancer screening and early diagnosis in India
V. Mangayarkarasi et al. National Library of Medicine / PMC. 2025.
Summary: This article reviews cancer screening methods and implementation challenges in India, including breast, cervical, lung, prostate, and oral cancers. It is useful for showing that early detection depends not only on technology, but also on workforce, awareness, affordability, and health-system reach.
Genomic-based early detection screening
E. Tizpa et al. National Library of Medicine / PMC. 2024.
Summary: This review explains how genomic approaches are being used to detect cancer signals in blood, urine, stool, and other samples. It places multi-cancer early detection within the larger movement toward molecular screening, while emphasizing that clinical benefit must be proven before broad adoption.
Multicancer early detection tests: a state-of-the-art review
E. Kennedy et al. National Library of Medicine / PMC. 2024.
Summary: This review summarizes current multi-cancer early detection tests, their biological targets, and their potential relevance for cancers of the head and neck and other sites. It explains why these tests are promising but still require careful integration with existing screening and diagnostic pathways.
The current system of cancer control
National Academies Press / NCBI Bookshelf. 2019.
Summary: This chapter reviews how cancer control depends on prevention, early detection, treatment, survivorship care, public education, and health-system coordination. It is a useful background source for understanding why medical breakthroughs matter most when they are connected to organized systems that reach real patients.
Blood test added to US colorectal cancer screening options
Reuters. Reuters. May 27, 2026.
Summary: The American Cancer Society added Guardant Health’s Shield blood test as an option in colorectal-cancer screening guidelines. Colonoscopy and stool tests remain stronger for finding precancerous lesions, but the blood test may help reach people who otherwise avoid screening, reinforcing the public-health idea that the best screening test is often the one a patient will complete.
FDA approves pembrolizumab with paclitaxel for platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma
U.S. Food and Drug Administration. FDA. February 10, 2026.
Summary: The FDA approved pembrolizumab with paclitaxel, with or without bevacizumab, for certain adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer whose tumors express PD-L1. The approval adds another immunotherapy-based option for a difficult-to-treat group of gynecologic cancers.
FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
U.S. Food and Drug Administration. FDA. March 25, 2026.
Summary: The FDA approved relacorilant with nab-paclitaxel for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have already received multiple prior treatments. The approval is notable because relacorilant targets the glucocorticoid receptor, offering a different biological strategy for tumors that have become resistant to standard platinum therapy.
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma
U.S. Food and Drug Administration. FDA. March 20, 2026.
Summary: The FDA approved nivolumab with doxorubicin, vinblastine, and dacarbazine for adults and children age 12 and older with previously untreated stage III or IV classical Hodgkin lymphoma. The decision moves immunotherapy earlier in treatment for a cancer where long-term cure and reducing late toxicities are major goals.
FDA approves teclistamab combination for relapsed or refractory multiple myeloma
U.S. Food and Drug Administration. FDA. March 5, 2026.
Summary: The FDA approved teclistamab with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy. Teclistamab is a bispecific antibody, part of a growing wave of immune-engaging cancer treatments designed to bring T cells into direct contact with cancer cells.
FDA grants traditional approval to encorafenib for BRAF V600E metastatic colorectal cancer
U.S. Food and Drug Administration. FDA. February 24, 2026.
Summary: The FDA granted traditional approval to encorafenib with cetuximab and fluorouracil-based chemotherapy for adults with metastatic colorectal cancer carrying a BRAF V600E mutation. The approval shows how molecular testing can separate colorectal cancers into biologically different groups with different treatment strategies.
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma
U.S. Food and Drug Administration. FDA. February 19, 2026.
Summary: The FDA approved acalabrutinib with venetoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The combination reflects a trend toward targeted, chemotherapy-free regimens that attack cancer survival pathways more precisely than older broad chemotherapy approaches.
FDA approves daratumumab combination for newly diagnosed multiple myeloma patients ineligible for transplant
U.S. Food and Drug Administration. FDA. January 27, 2026.
Summary: The FDA approved daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who cannot receive autologous stem-cell transplant. This expands a powerful antibody-based regimen to patients who may be older or medically less able to tolerate intensive therapy.
Cancer vaccine sustains melanoma reduction after five years
NYU Langone Health. Medical Xpress. June 1, 2026.
Summary: Five-year follow-up data showed that an individualized mRNA cancer vaccine combined with pembrolizumab continued to reduce the risk of melanoma recurrence or death after surgery. The results support the idea that vaccines can train the immune system to recognize a patient’s own tumor mutations and maintain long-term anticancer memory.
Cancer vaccines could transform treatment and prevention, but misinformation remains a threat
Julie K. Bauman and Thomas Marron. Medical Xpress. March 22, 2026.
Summary: This article explains how mRNA cancer vaccines differ from infectious-disease vaccines and why they may become important in cancer treatment and prevention for high-risk patients. It also warns that vaccine misinformation could slow adoption even when strong evidence emerges.
From immune evasion to activation: a new cancer vaccine strategy
University of Chicago Medical Center. Medical Xpress. January 13, 2026.
Summary: Researchers reported a vaccine strategy called iVAC that can enter tumor cells, dismantle immune-evasion defenses, and help turn the tumor into a source of immune activation. The work is early and experimental, but it addresses a major problem in oncology: tumors that remain “cold” and invisible to immune attack.
Emerging biomarkers for early cancer detection and diagnosis
S. Zafar et al. National Library of Medicine / PMC. 2025.
Summary: This review summarizes emerging cancer biomarkers being studied for earlier and more accurate diagnosis. It covers non-invasive testing approaches, including blood-based and molecular markers, and explains why validation, accuracy, and clinical usefulness are essential before new tests become standard care.
Challenges in the future of cancer screening
E. Lynge. National Library of Medicine / PMC. 2025.
Summary: This review examines the future of cancer screening, including the goal of reducing mortality while avoiding overdiagnosis and unnecessary harm. It is useful for understanding why screening programs must balance early detection with evidence that earlier diagnosis actually improves health outcomes.
Optimal cervical cancer screening strategies for unvaccinated women
D. D. de Bondt et al. National Library of Medicine / PMC. 2026.
Summary: Researchers modeled cervical-cancer screening strategies for unvaccinated women, focusing on HPV testing and screening frequency. The article reinforces the public-health importance of screening for people who did not benefit from HPV vaccination, especially as countries move toward cervical-cancer elimination.
Cervical cancer elimination in Australia and the Asia Pacific
S. Yuill et al. National Library of Medicine / PMC. 2026.
Summary: This article reviews progress toward cervical-cancer elimination in Australia and the Asia Pacific. Australia’s combination of HPV vaccination, HPV-based screening, and treatment of precancerous disease offers a model for how cancer prevention can become a realistic public-health goal.
Perspective: a life course approach to primordial prevention of cardiovascular disease
S. Mendis. National Library of Medicine / PMC. 2026.
Summary: This article argues that cardiovascular prevention should begin before risk factors become established, using a life-course approach that includes healthier environments, vaccination where relevant, better nutrition, physical activity, and early risk reduction. It shifts the focus from treating disease to preventing the conditions that make disease likely.
AI uses sleep study data to predict dozens of future health issues
Reuters. Reuters. January 7, 2026.
Summary: Researchers reported that artificial intelligence could use brain recordings from one night of sleep-lab data to predict risk for more than 100 health conditions. The work is an example of preventive medicine moving toward deeper use of existing clinical data to identify people who may need earlier monitoring or intervention.
Novel approach to HIV vaccine shows early promise
Reuters. Reuters. May 16, 2025.
Summary: Early human trials of a germline-targeting HIV vaccine strategy showed promise in activating the rare immune cells needed to make broadly neutralizing antibodies. The work is still preliminary, but it represents one of the most important scientific paths toward a long-sought preventive HIV vaccine.
Experimental flu drug with compound found in chocolate tops Tamiflu in early study
Reuters. Reuters. August 6, 2025.
Summary: Researchers reported early evidence that a flu-treatment strategy combining theobromine with a synthetic compound outperformed Tamiflu in preliminary studies. The approach targets viral ion channels, a mechanism that could potentially support broader antiviral drug development, though much more testing is needed before clinical use.
Mailing stool-test kits boosts colorectal cancer screening
Reuters. Reuters. August 6, 2025.
Summary: Research highlighted by Reuters found that mailing stool-test kits increased colorectal-cancer screening participation. This is a practical public-health win because access and convenience can determine whether prevention programs reach people before cancer becomes advanced.
FDA grants accelerated approval to avutometinib and defactinib for KRAS-mutated low-grade serous ovarian cancer
U.S. Food and Drug Administration. FDA. May 8, 2025.
Summary: The FDA granted accelerated approval to avutometinib and defactinib for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy. The approval is significant because low-grade serous ovarian cancer can be slow-growing but difficult to treat, and KRAS-targeted strategies offer a more biologically specific approach.
FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
U.S. Food and Drug Administration. FDA. June 11, 2025.
Summary: The FDA approved taletrectinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The approval adds another targeted option for patients whose tumors are driven by a specific gene rearrangement, reinforcing the value of molecular testing at diagnosis.
FDA approves retifanlimab with chemotherapy for squamous cell carcinoma of the anal canal
U.S. Food and Drug Administration. FDA. May 15, 2025.
Summary: The FDA approved retifanlimab with carboplatin and paclitaxel for first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. Anal cancer is strongly linked to HPV, making this article relevant both to treatment advances and the long-term prevention value of HPV vaccination.
FDA grants accelerated approval to telisotuzumab vedotin for NSCLC with high c-Met overexpression
U.S. Food and Drug Administration. FDA. May 14, 2025.
Summary: The FDA granted accelerated approval to telisotuzumab vedotin-tllv for adults with previously treated non-squamous non-small cell lung cancer whose tumors show high c-Met protein overexpression. This antibody-drug conjugate approval is another example of cancer care moving toward measurable tumor features rather than one-size-fits-all treatment.
FDA approves belzutifan for pheochromocytoma or paraganglioma
U.S. Food and Drug Administration. FDA. May 14, 2025.
Summary: The FDA approved belzutifan for adults and children age 12 and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. The approval was the first oral therapy approved for these rare tumors, giving patients a targeted option where choices have been limited.
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease
U.S. Food and Drug Administration. FDA. May 15, 2026.
Summary: The FDA approved atezolizumab and a subcutaneous atezolizumab-hyaluronidase formulation as adjuvant treatments for adults with muscle-invasive bladder cancer after cystectomy when a blood test shows circulating tumor DNA molecular residual disease. This is important because it uses a measurable sign of leftover cancer biology to guide post-surgery immunotherapy.
FDA approves oral combination for newly diagnosed acute myeloid leukemia
U.S. Food and Drug Administration. FDA. May 13, 2026.
Summary: The FDA approved an oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia in adults age 75 and older, or in adults whose health conditions make intensive induction chemotherapy unsuitable. The approval reflects a continued move toward more tolerable treatment options for older leukemia patients.
FDA approves zenocutuzumab-zbco for advanced cholangiocarcinoma with NRG1 gene fusion
U.S. Food and Drug Administration. FDA. May 8, 2026.
Summary: The FDA approved zenocutuzumab-zbco, sold as Bizengri, for adults with advanced, unresectable, or metastatic cholangiocarcinoma whose tumors carry a rare NRG1 gene fusion. The approval shows how molecular testing can reveal small patient groups who may benefit from highly targeted cancer therapies.
FDA approves expanded use of Sanofi's type 1 diabetes drug
Reuters. Reuters. June 12, 2026.
Summary: The FDA expanded use of Sanofi’s Tzield for children ages 8 to 17 who were recently diagnosed with stage 3 type 1 diabetes. The drug is designed to preserve insulin-producing cells by modulating the immune attack that drives the disease, although it carries serious safety warnings and requires careful clinical oversight.
FDA clears first over-the-counter continuous glucose monitor for children
U.S. Food and Drug Administration. FDA. June 12, 2026.
Summary: The FDA cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use in children, including those with diabetes who use oral medication and people tracking how diet, exercise, and lifestyle affect glucose. The clearance could make glucose monitoring more accessible to families and young patients.
US FDA approves MannKind's inhaled insulin for children
Reuters. Reuters. May 29, 2026.
Summary: The FDA approved MannKind’s inhaled insulin Afrezza for children age six and older with type 1 or type 2 diabetes. The approval gives some pediatric patients a needle-free mealtime insulin option, though the treatment requires medical screening and carries warnings about possible lung-related side effects.
FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals
Reuters. Reuters. April 28, 2026.
Summary: The FDA launched a pilot program to monitor clinical trial data in real time, aiming to reduce delays in drug review and potentially shorten approval timelines. If successful, the model could speed access to important therapies while giving regulators earlier visibility into trial safety and effectiveness signals.
FDA launches a digital health devices pilot
U.S. Food and Drug Administration. FDA. April 24, 2026.
Summary: The FDA launched the Technology-Enabled Meaningful Patient Outcomes pilot for digital health devices. The program is intended to promote access to selected digital tools while protecting patient safety, reflecting the growing role of software, sensors, remote monitoring, and connected devices in chronic-care prevention.
NIH launches new office to advance human-based research and reduce animal use
National Institutes of Health. NIH. June 15, 2026.
Summary: NIH launched a new office to coordinate development, validation, and scaling of human-based research models that can reduce reliance on animal testing. The effort could improve biomedical research by expanding organoids, tissue chips, computational models, and other systems that may better predict human biology.
Cancer statistics, 2026
Rebecca L. Siegel et al. CA: A Cancer Journal for Clinicians / PMC. 2026.
Summary: The American Cancer Society projected more than 2.1 million new cancer cases and more than 626,000 cancer deaths in the United States in 2026. The report provides a broad statistical foundation for understanding why prevention, screening, early detection, and equitable access to treatment remain central cancer priorities.
Early Cancer Detection: What's Going on and What's Next
E. Di Carlo. National Library of Medicine / PMC. 2026.
Summary: This article reviews the current state of early cancer detection, including multi-cancer early-detection platforms, biomarkers, imaging, and clinical implementation challenges. It is useful because it explains both the promise of finding cancer earlier and the evidence needed before new screening tools become routine.
Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch syndrome
MD Anderson Cancer Center. MD Anderson Cancer Center. January 16, 2026.
Summary: Researchers reported that the investigational NOUS-209 vaccine safely stimulated immune responses against precancerous and cancerous cells in people with Lynch syndrome. The study is important because it explores cancer interception, the idea of training the immune system before inherited cancer risk becomes invasive disease.
Preventing cancer through vaccination: progress, promise, and key trials
Union for International Cancer Control. UICC. August 22, 2025.
Summary: This article reviews how vaccines can prevent cancers caused by infections, especially HPV and hepatitis B, while also discussing newer therapeutic and preventive cancer-vaccine trials. It connects established public-health wins with experimental approaches that may one day prevent cancer in high-risk groups.
From Cancer Research to Prevention and Screening
Summary: This article emphasizes that cancer progress is not only about new drugs, but also prevention, lifestyle changes, and early detection through appropriate screening. It is useful as a general prevention-focused overview of how public health and biomedical research work together to reduce cancer deaths.
Cancer Prevention and Early Detection Facts & Figures 2025-2026
American Cancer Society. American Cancer Society. March 5, 2025.
Summary: The American Cancer Society report summarizes U.S. data on cancer screening, vaccination, tobacco use, obesity, infectious causes of cancer, and other preventable risks. It is a strong reference for showing how prevention and early detection can reduce cancer burden when programs reach enough people.
New evidence confirms malaria vaccine saves child lives and will have high impact in wider rollout
World Health Organization. WHO. May 8, 2026.
Summary: WHO reported new evidence from Ghana, Kenya, and Malawi showing that the RTS,S malaria vaccine saved lives in real public-health use. The update supports wider rollout of malaria vaccination as part of a prevention package that also includes bed nets, testing, treatment, and seasonal protection.
Global health leaders reaffirm commitment to Immunization Agenda 2030
World Health Organization. WHO. May 26, 2026.
Summary: Global health leaders warned that progress toward Immunization Agenda 2030 is off track because of measles outbreaks, declining routine coverage in several regions, and widening inequalities in vaccine access. The article highlights the importance of rebuilding trust, financing, and delivery systems for routine immunization.
World cannot afford complacency on vaccines
World Health Organization. WHO. June 9, 2026.
Summary: WHO’s immunization director emphasized that vaccines are essential not only for disease prevention, but also for resilient health systems, global health security, and equity. The message links vaccine coverage to broader public-health strength, especially as preventable outbreaks return in under-immunized communities.
For every generation, vaccines work
World Health Organization Regional Office for Europe. WHO Europe. April 20, 2026.
Summary: WHO Europe highlighted vaccination as protection across the life course, from childhood to pregnancy, older adulthood, and cancer prevention through HPV vaccination. The article is useful because it frames immunization as lifelong preventive care rather than a one-time childhood intervention.
World Health Day 2026: Together for health. Stand with science
World Health Organization. WHO. April 7, 2026.
Summary: WHO used World Health Day 2026 to call for support for science, health workers, and health systems. The campaign connects medical breakthroughs to the public-health institutions needed to deliver them, especially during periods of misinformation, funding pressure, and uneven access.
World health statistics 2026: monitoring health for the SDGs
World Health Organization. WHO. May 2026.
Summary: WHO’s 2026 World Health Statistics report consolidates global data on health-related Sustainable Development Goal indicators, healthy life expectancy, premature mortality, immunization inequalities, and health-system progress. It is a broad reference for measuring whether prevention and public-health programs are actually improving lives.
Global health gains face threat of reversal
World Health Organization. WHO. May 13, 2026.
Summary: WHO warned that global health progress remains fragile despite real gains. The article points to gaps in data, health-system resilience, and financing, arguing that stronger prevention and better primary care are needed to protect improvements in life expectancy and disease control.
Unsafe food causes 866 million illnesses and 1.5 million deaths annually
World Health Organization. WHO. June 4, 2026.
Summary: WHO reported that unsafe food causes hundreds of millions of illnesses and about 1.5 million deaths each year, with young children facing especially high risk. The article is a reminder that prevention includes food safety, clean supply chains, regulation, surveillance, and public education.
Global hepatitis report 2026
World Health Organization. WHO. 2026.
Summary: WHO’s hepatitis report reviews progress and gaps in preventing, diagnosing, and treating hepatitis B and C. Because chronic viral hepatitis can lead to liver failure and liver cancer, vaccination, testing, harm reduction, and antiviral treatment are major tools of preventative health.
Efforts to eliminate hepatitis deliver gains but more action needed to meet 2030 targets
World Health Organization. WHO. April 28, 2026.
Summary: WHO reported gains in the fight against hepatitis while warning that countries remain off track for elimination targets. The article highlights practical prevention steps, including hepatitis B vaccination, expanded testing, safer health-care practices, and treatment access for hepatitis C.
Why we still lack a global fitness plan and how to fix it
UC San Diego Today. UC San Diego. April 9, 2026.
Summary: Public-health experts argued that physical activity is still treated as a “policy orphan” even though it prevents disease and supports healthier aging. The article calls for transport, education, recreation, health, and urban-planning sectors to share responsibility for making daily movement easier.
Exercise harder, not just longer, to reduce risk of disease and death
European Society of Cardiology. ESC. March 30, 2026.
Summary: Research published in the European Heart Journal found that even a few minutes of vigorous daily activity was linked to lower risk of several major diseases, including heart disease and dementia. The findings suggest that intensity can matter, though any exercise plan should fit a person’s health status and abilities.
Global physical activity levels have not improved over 20 years
Nature Asia. Nature Portfolio. March 10, 2026.
Summary: A Nature Medicine analysis found that global physical activity levels have not meaningfully improved over two decades. The report underscores the need for population-level prevention strategies, including walkable communities, safer public spaces, active transportation, and policies that reduce sedentary lifestyles.
Physical activity types, variety, and mortality
Summary: This study found that many types of physical activity were associated with lower mortality and that variety in activity was also linked to better survival. The findings support a practical prevention message: people may benefit from mixing walking, cycling, sports, strengthening, household activity, and other movement.
Scientists find changing your diet after 45 adds over 3 years to your life
Prevention. Prevention. March 2026.
Summary: This article covers research suggesting that adopting a healthier, plant-forward diet after age 45 may add years to life expectancy. The finding supports the idea that nutrition changes can still matter in midlife, especially when they increase whole grains, fruits, vegetables, and other nutrient-rich foods.
Minimum combined sleep, physical activity, and nutrition improvements associated with life expectancy gains
N. A. Koemel et al. eClinicalMedicine. 2026.
Summary: Researchers modeled how small combined improvements in sleep, physical activity, and nutrition could relate to life expectancy. The study supports a realistic public-health message that modest progress across several habits may be more achievable and meaningful than trying to perfect one lifestyle factor.
FDA Clears First Blood Test to Help Diagnose Alzheimer’s Disease
U.S. Food and Drug Administration. FDA. May 16, 2025.
Summary: The FDA cleared the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test to help diagnose Alzheimer’s disease in adults 55 and older who already have signs or symptoms of cognitive decline. The test offers a less invasive alternative to spinal-fluid testing or PET imaging, while still requiring interpretation alongside a full clinical evaluation.
WHO recommends injectable lenacapavir for HIV prevention
World Health Organization. WHO. July 14, 2025.
Summary: WHO recommended twice-yearly injectable lenacapavir as an additional HIV prevention option. Because it requires only two doses a year, the drug could improve adherence and give people at risk of HIV another long-acting prevention choice alongside condoms, oral PrEP, testing, and community outreach.
FDA approval of injectable lenacapavir marks progress for HIV prevention
World Health Organization. WHO. June 19, 2025.
Summary: WHO welcomed the FDA approval of lenacapavir for HIV prevention, describing it as an important advance in the global HIV response. The article highlights the public-health promise of a twice-yearly PrEP option, especially for people who face barriers to daily oral medication.
US FDA approves Gilead’s twice-yearly injection for HIV prevention
Reuters. Reuters. June 18, 2025.
Summary: The FDA approved Gilead’s lenacapavir, sold as Yeztugo, as a twice-yearly injectable drug for HIV prevention in adults and adolescents at risk. The approval was based on large clinical trials showing very high protection, making it one of the most significant prevention advances in HIV medicine in years.
FDA approves novel non-opioid treatment for moderate to severe acute pain
U.S. Food and Drug Administration. FDA. January 30, 2025.
Summary: The FDA approved suzetrigine, sold as Journavx, as a first-in-class non-opioid treatment for moderate to severe acute pain in adults. The drug targets pain-signaling pathways in the peripheral nervous system, offering a new approach at a time when safer alternatives to opioids remain a major public-health need.
FDA approves first gene therapies to treat patients with sickle cell disease
U.S. Food and Drug Administration. FDA. December 8, 2023.
Summary: The FDA approved Casgevy and Lyfgenia, the first cell-based gene therapies for sickle cell disease. Casgevy also became the first FDA-approved treatment using CRISPR/Cas9 gene editing, marking a major milestone for genetic medicine and for patients with recurrent vaso-occlusive crises.
FDA approves new non-opioid pain drug
Katie Kingwell. Nature Reviews Drug Discovery. January 30, 2025.
Summary: This article explains the significance of suzetrigine’s approval as a new non-opioid pain medicine. It places the decision in context, noting the long gap in new pain-drug classes and the need for treatments that relieve acute pain without the addiction risks associated with opioids.
FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
A. Singh et al. National Library of Medicine / PMC. 2024.
Summary: This review discusses Casgevy as the first FDA-approved CRISPR/Cas9-based therapy for sickle cell disease. It explains the science behind editing a patient’s own blood-forming stem cells and also discusses access, safety, cost, and long-term monitoring questions.
Blood tests can now detect Alzheimer’s. Should you get one?
The Wall Street Journal. The Wall Street Journal. June 2026.
Summary: This article examines the rapid arrival of blood tests that detect Alzheimer’s-related proteins. It explains why these tests could make diagnosis easier for people with symptoms, while also warning that they are not currently recommended as broad screening tools for healthy people.
Digitally enriching a screening population for pancreatic cancer using routine blood-based measures and clinical histories
Chris Varghese et al. arXiv. May 28, 2026.
Summary: Researchers developed a machine-learning model that uses routine blood-test patterns and medical histories to identify people at elevated risk of pancreatic cancer years before diagnosis. The work is still preclinical, but it points toward a future where ordinary health records help target high-risk screening.
Early and prediagnostic detection of pancreatic cancer from computed tomography
Wenxuan Li et al. arXiv. January 29, 2026.
Summary: This study describes an AI system designed to detect subtle signs of pancreatic cancer on CT scans before the disease is formally diagnosed. Because pancreatic cancer is often found late, tools that flag overlooked early imaging clues could eventually help move more patients toward earlier treatment.
Diagnostic accuracy, fairness and clinical implementation of AI in breast cancer screening
C. J. Kelly et al. Nature Cancer. 2026.
Summary: This study found that an AI system could match or exceed specialist radiologist performance in breast-cancer screening across diverse UK populations and workflows. The research is important because it addresses not only accuracy, but also fairness and real-world implementation.
Using AI to detect breast cancer
Breastcancer.org. Breastcancer.org. Updated 2026.
Summary: This explainer describes how artificial intelligence is being used in breast imaging to help detect cancers, reduce missed findings, and estimate future risk. It also makes clear that AI is a support tool rather than a replacement for trained clinicians and established screening programs.
The future of cancer detection could be just a blood test away, say scientists
ecancer. ecancer. December 4, 2025.
Summary: Scientists described progress toward blood and urine tests that use AI and biomarkers such as exosomes to detect cancer earlier. The article captures the excitement around less invasive cancer detection while also making clear that these tools still need validation before broad clinical use.
XGBoost-powered digital twins leverage routine blood tests for early detection of cancer and cardiovascular disease
Lo Kai Shun John et al. arXiv. November 18, 2025.
Summary: This study tested machine-learning “digital blood twin” models built from routine blood tests, demographics, diagnoses, and medication data. The approach showed proof-of-concept potential for low-cost risk prediction for colorectal cancer, broad cancer categories, and cardiovascular disease.
Current AI technologies in cancer diagnostics and treatment
A. Tiwari et al. Molecular Cancer. 2025.
Summary: This review summarizes how AI is being used in cancer diagnosis, imaging, pathology, treatment planning, and early detection. It includes examples such as tools that scan radiology reports for signs of pancreatic cancer, showing how AI may help reduce missed or delayed diagnoses.
For every generation, vaccines work
World Health Organization Regional Office for Europe. WHO Europe. April 20, 2026.
Summary: WHO Europe used World Immunization Week to highlight how vaccines protect people across the lifespan, including HPV vaccination for cervical-cancer prevention. The article emphasizes that vaccination is not only childhood protection, but a lifelong prevention tool.
How community health workers are improving vaccine delivery in Africa
Mallika Raghavan and Rebecca Alban. Gavi VaccinesWork. February 10, 2026.
Summary: This article explains how community health workers help reach children who miss routine immunization. It focuses on trust, local knowledge, household outreach, and the need to support grassroots health workers as essential parts of preventive health systems.
From Scarcity to Security: How Kenya is Turning the Tide on Vaccine Availability
Global Health Advocacy Incubator. GHAI. February 12, 2026.
Summary: This article describes Kenya’s effort to strengthen vaccine financing, supply security, and immunization resilience after shortages disrupted services. It frames reliable vaccine access as a prevention issue and shows how policy, budgeting, and local advocacy can protect routine immunization.
Kenya pivots to prevention-led health security as new national frameworks launched
Government Advertising Agency, Kenya. GAA. March 31, 2026.
Summary: Kenya launched public-health security frameworks focused on preparedness, prevention, and system resilience. The article highlights a shift from reacting to outbreaks toward building institutions that can prevent, detect, and respond to health threats before they become crises.
Global hepatitis report 2026
World Health Organization. WHO. 2026.
Summary: WHO’s 2026 hepatitis report reviews global progress against hepatitis B and hepatitis C, both major causes of liver cancer and preventable death. The report stresses vaccination, testing, treatment, harm reduction, and stronger primary-care systems as key tools for elimination.
Efforts to eliminate hepatitis deliver gains but more action needed to meet 2030 targets
World Health Organization. WHO. April 28, 2026.
Summary: WHO reported progress in hepatitis elimination while warning that the world is still off track for 2030 targets. The update is important for preventative health because hepatitis B vaccination and hepatitis C treatment can prevent liver failure and liver cancer.
OB-GYN group makes vaccine recommendations for the first time
Associated Press. AP News. June 2026.
Summary: The American College of Obstetricians and Gynecologists issued its own immunization schedule for pregnant, postpartum, and breastfeeding patients. The recommendations include flu, COVID-19, Tdap, and RSV vaccines, aiming to give clinicians clear guidance amid confusion over federal vaccine policy.
Leading OB-GYN group breaks from CDC on maternal vaccination schedule
Jessica Glenza. The Guardian. June 16, 2026.
Summary: ACOG released maternal vaccine guidance recommending core vaccines during pregnancy to protect both pregnant patients and newborns. The article shows how professional medical groups are trying to preserve evidence-based prevention guidance during a period of public-health controversy.
Physical activity for public health in the 21st century
D. Salvo et al. Nature Medicine. 2026.
Summary: This review argues that physical inactivity remains a major global public-health problem linked to millions of deaths each year. It calls for prevention strategies that go beyond individual willpower, including active transportation, safer public spaces, equitable recreation, and policy changes that make movement easier.
Massive study uncovers how much exercise is needed to live longer
American Medical Association. AMA. 2026.
Summary: The AMA summarized evidence showing that people who exceed minimum physical-activity recommendations can gain additional longevity benefits. The article helps translate exercise research into practical prevention advice while reinforcing that some movement is still far better than none.
Five healthy habits for longevity in your 40s and 50s
Sarah Williams. Stanford Medicine. January 7, 2026.
Summary: Stanford Medicine experts described midlife habits that can protect health and vitality later in life, including physical activity, nutrition, sleep, social connection, and preventive care. The article is useful because it frames the 40s and 50s as a crucial window for long-term disease prevention.
We asked a longevity doctor which daily habit matters most for healthy aging
Verywell Health. Verywell Health. June 2026.
Summary: This article focuses on aerobic exercise as a core daily habit for healthy aging. It explains how regular movement supports cardiovascular health, metabolism, inflammation control, and cellular pathways linked to aging, while emphasizing that even modest activity can help.
Nutrition
World Health Organization. WHO. 2026.
Summary: WHO explains that good nutrition supports child development, immune function, safe pregnancy, lower risk of noncommunicable disease, and longevity. The page is a useful public-health foundation for articles about food policy, chronic disease prevention, maternal health, and healthy aging.
Five key health and nutrition megatrends for 2026
Kerry Health and Nutrition Institute. KHNI. 2026.
Summary: This trend report identifies major nutrition themes for 2026, including gut health, women’s health, healthy aging, protein quality, and food systems connected to sustainability. It is useful for tracking where nutrition science, consumer behavior, and preventive-health messaging are moving.
GLP-1 users may be making a major weight-loss mistake, new study suggests
New York Post. New York Post. June 17, 2026.
Summary: A study presented at ENDO 2026 suggested that some people using GLP-1 weight-loss medications may reduce their physical activity after starting treatment. The article highlights the importance of exercise, strength training, and clinical monitoring during medication-assisted weight loss to preserve muscle and metabolic health.
Cancer Treatment Breakthroughs
Cancer in 2026: How Immunotherapy Is Reshaping the Odds
Cancer Research Institute. Cancer Research Institute. February 20, 2026.
Summary: This article reviews how immunotherapy has changed cancer survival, with the overall five-year cancer survival rate reaching about 70% while some cancers still lag far behind. It explains why researchers are working to expand immune-based treatments into harder-to-treat tumors such as pancreatic cancer, ovarian cancer, and some forms of colorectal cancer.
Experts Forecast Cancer Research and Treatment Advances in 2026
American Association for Cancer Research. AACR. January 8, 2026.
Summary: Cancer experts previewed major 2026 priorities, including earlier cancer detection, cancer interception before disease becomes advanced, personalized treatment, artificial intelligence, and better access to care. The article is useful because it connects individual breakthroughs to the broader direction of oncology research.
Personalized Cancer Vaccine Shows Durable Benefit at 5 Years
American Association for Cancer Research. PubMed. March 2, 2026.
Summary: Five-year data from the KEYNOTE-942 trial showed that a personalized mRNA cancer vaccine combined with pembrolizumab continued to reduce the risk of melanoma recurrence or death. The result strengthens the case for personalized neoantigen vaccines, though larger phase III trials are still needed before this becomes routine care.
The New Wave of Gene and Cell Therapies Across Diseases
A. Rieske. National Library of Medicine / PMC. 2026.
Summary: This review explains why gene and cell therapies have advanced rapidly between 2023 and 2026, citing improvements in delivery systems, precision editing, manufacturing, and safety. It covers therapies across multiple diseases and helps place cancer cell therapy, rare-disease gene therapy, and regenerative medicine in a shared scientific context.
Recent advances and future prospects of immunotherapeutic strategies in prostate cancer
N. Wang et al. National Library of Medicine / PMC. 2026.
Summary: This review summarizes new immunotherapy strategies for prostate cancer, including therapeutic vaccines, immune checkpoint inhibitors, CAR T-cell therapy, and bispecific antibodies. Prostate cancer has been difficult to treat with immunotherapy, so the article is useful for understanding both the promise and the barriers.
Evaluation of RC48-ADC in Combination with PRaG Regimen for Advanced Solid Tumors
M. Xu et al. National Library of Medicine / PMC. 2026.
Summary: Researchers studied the antibody-drug conjugate disitamab vedotin, also known as RC48, combined with PD-1 inhibition, radiotherapy, and GM-CSF in HER2-expressing advanced solid tumors. The study reflects the growing strategy of combining targeted cancer drugs with immune activation and radiation.
Cancer Prevention and Early Detection
In five cancer types, prevention and screening have been major contributors to saving lives
National Institutes of Health. NIH. December 5, 2024.
Summary: An NIH-led modeling study found that prevention and screening saved more lives than treatment advances across breast, cervical, colorectal, lung, and prostate cancer over 45 years. The article is especially important for preventative health because it shows that vaccines, screening, tobacco reduction, and early detection can be as powerful as new drugs.
FDA approves Waters' at-home cervical cancer screening kit
Reuters. Reuters. April 8, 2026.
Summary: The FDA cleared Waters Corporation’s at-home cervical cancer screening kit for use with an approved HPV test. Home-based screening could help reach people who avoid or cannot access clinic-based screening, making it a potentially important tool for preventing cervical-cancer deaths.
2026 Early Detection Survey
Prevent Cancer Foundation. Prevent Cancer Foundation. 2026.
Summary: The Prevent Cancer Foundation reported that cost worries are now a major reason many U.S. adults fall behind on cancer screening. The survey found that many adults are overdue for at least one routine screening, highlighting that early-detection technology is not enough unless people can afford and access it.
Cancer Early Detection and Screening Research
National Cancer Institute. NCI Division of Cancer Prevention. 2026.
Summary: The National Cancer Institute describes research programs focused on discovering, validating, and improving cancer screening tools. The page is useful as a hub for early-detection science because it includes biomarkers, imaging, risk prediction, and screening strategies aimed at lowering cancer deaths.
Early Detection and Diagnosis Research
Cancer Research UK. Cancer Research UK. 2026.
Summary: Cancer Research UK explains its roadmap for finding cancer earlier and diagnosing it faster. The program focuses on shifting diagnosis to earlier stages, improving tests, and building health-system capacity so early-detection discoveries can actually reach patients.
Beth Israel starts using AI-driven tool to spot breast cancer risk
Steph Solis. Axios Boston. February 23, 2026.
Summary: Beth Israel Deaconess Medical Center began using Clairity Breast, an AI tool designed to estimate breast-cancer risk from mammograms up to five years in advance. The tool points toward a future where screening does not only find existing cancer but also identifies people who may need closer monitoring.
How the FDA's stance on breakthrough AI is evolving
Katie Palmer. STAT. April 2, 2026.
Summary: This article examines how the FDA is handling AI medical devices that seek breakthrough designation, including tools aimed at detecting cancer across many tissues. It is useful for understanding both the promise of AI diagnostics and the regulatory challenge of proving these systems work safely in real clinical settings.
Vaccines and Public Health Wins
New evidence confirms malaria vaccine saves child lives and will have high impact in wider rollout
World Health Organization. WHO. May 8, 2026.
Summary: WHO reported new evidence from Ghana, Kenya, and Malawi showing that the RTS,S malaria vaccine reduced child deaths in public-health use. This is a major preventative-health milestone because malaria remains one of the world’s biggest killers of young children.
Global Vaccine Introduction and Implementation Report
VIEW-hub. International Vaccine Access Center. February 10, 2026.
Summary: This report tracks global vaccine introductions, including HPV vaccine expansion in Angola and Ukraine in early 2026. It is useful for documenting how cancer-prevention vaccines are moving into more national immunization programs, even as countries face funding and delivery challenges.
Africa's routine vaccine systems deliver gains against cancer and malaria despite funding pressures
Summary: Gavi reported that African routine immunization systems are helping expand HPV vaccination for cervical-cancer prevention and malaria vaccination for child survival. The article emphasizes country-led vaccine budgeting and prioritization as a way to protect immunization progress during funding constraints.
Cervical Cancer Elimination Initiative
World Health Organization. WHO. 2026.
Summary: WHO’s cervical-cancer elimination strategy combines HPV vaccination, screening, and treatment of precancerous disease. The initiative is one of the clearest examples of a cancer that could be reduced to a rare public-health problem through prevention and early intervention.
Advancing Adult HPV Vaccination: Turning Evidence into Action
M. Gosalia et al. Vaccines. 2026.
Summary: This article reviews efforts to improve adult HPV vaccination, especially for people who remain at risk but missed vaccination when younger. It highlights policy, education, and access barriers that must be addressed if HPV vaccination is to prevent more cervical, anal, throat, and other HPV-related cancers.
AMA joins effort to launch vaccine science review amid CDC turmoil
The Washington Post. The Washington Post. February 10, 2026.
Summary: The American Medical Association and the University of Minnesota’s Vaccine Integrity Project launched an independent vaccine-science review effort focused on evidence around flu, COVID-19, RSV, and HPV vaccines. The article is important because it shows medical groups trying to protect trust in vaccine evidence during political conflict over public-health guidance.
Nutrition, Exercise, and Longevity
Two simple habits may outperform a popular longevity wonder drug: study
Adriana Diaz. New York Post. June 16, 2026.
Summary: A long-term JAMA study found that lifestyle changes, including a healthy diet and at least 150 minutes of weekly physical activity, outperformed metformin in reducing the risk of developing multiple chronic conditions. The finding supports the idea that ordinary prevention habits can have larger long-term health effects than a single anti-aging drug.
To Live Longer, One Surprising Factor Matters As Much As Exercise
Verywell Health. Verywell Health. June 2026.
Summary: A 2026 study linked leisure activities such as reading, art, music, hobbies, and cultural outings to healthier biological aging. The article broadens the idea of prevention beyond diet and exercise, suggesting that social, creative, and mentally stimulating activities may also support long-term health.
This one change to your exercise routine could add years
ScienceDaily. ScienceDaily. April 26, 2026.
Summary: Research published in BMJ Medicine found that variety in physical activity may help extend lifespan, not just total exercise time. The study suggests that mixing different types of movement may provide broader benefits than relying on only one form of exercise.
Even small changes in physical activity may boost longevity
Harvard Health Publishing. Harvard Health Publishing. February 19, 2026.
Summary: Harvard Health summarized research estimating that adding just a few minutes of moderate-to-vigorous activity each day could prevent a meaningful share of deaths at the population level. The article is useful because it frames exercise prevention around small, realistic changes rather than intimidating fitness goals.
Physical activity for public health in the 21st century
D. Salvo et al. Nature Medicine. 2026.
Summary: This Nature Medicine review argues that physical inactivity remains a major global public-health problem linked to millions of deaths each year. It calls for prevention strategies that go beyond individual advice, including safer streets, active transport, equitable recreation spaces, and policies that make movement easier.
Minimum combined sleep, physical activity, and nutrition improvements associated with life expectancy gains
N. A. Koemel et al. eClinicalMedicine. 2026.
Summary: This study found that small combined improvements in sleep, physical activity, and nutrition were associated with theoretical gains in life expectancy. The article supports a practical prevention message: modest improvements across several habits may matter more than trying to perfect one health behavior.
Community Health and Health Systems
Long-Term Health and Human Capital Effects of Universal Health Care and Mass Literacy: Evidence from Cuba
Giovanni Mellace and Rok Spruk. arXiv. May 28, 2026.
Summary: This study used synthetic-control methods to estimate the long-term effects of Cuba’s 1961 national health service and literacy campaign. The authors found large, persistent improvements in infant mortality and schooling, suggesting that broad public-health and education investments can produce lasting population-health gains.
US postpones third consecutive meeting of preventive health panel
Reuters. Reuters. March 3, 2026.
Summary: Reuters reported that the U.S. Preventive Services Task Force postponed another meeting, raising concern among health groups because the panel’s recommendations influence insurance coverage for cancer screenings and other preventive services. The article is a reminder that prevention depends not only on science, but also on functioning public-health institutions.
Only half of U.S. adults trust the CDC's public health recommendations, poll finds
Linley Sanders. PBS NewsHour. June 2026.
Summary: A poll found declining trust in CDC public-health recommendations, especially after years of pandemic conflict and political pressure. The article matters for preventative health because vaccines, screening, outbreak response, and nutrition guidance all depend on public confidence in health institutions.
FDA approves new drug for triple-negative breast cancer
U.S. Food and Drug Administration. FDA. May 22, 2026.
Summary: The FDA approved datopotamab deruxtecan-dlnk, sold as Datroway, for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy. Triple-negative breast cancer is often harder to treat because it lacks common hormone and HER2 targets, making new antibody-drug conjugates an important area of progress.
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
U.S. Food and Drug Administration. FDA. June 12, 2026.
Summary: The FDA approved belzutifan with pembrolizumab for adults with clear-cell renal cell carcinoma at intermediate-high or high risk of recurrence after kidney surgery. The approval is important because it moves a targeted therapy combination into the post-surgery setting, where the goal is preventing cancer from coming back.
US FDA approves BeOne's drug for a type of blood cancer
Reuters. Reuters. May 13, 2026.
Summary: The FDA granted accelerated approval to BeOne Medicines’ Beqalzi for relapsed or refractory mantle cell lymphoma. The drug targets BCL-2, a protein that helps cancer cells survive, and represents the first BCL-2 inhibitor approved specifically for this rare and aggressive blood cancer.
ASCO 2026: pancreatic cancer breakthrough, head and neck cancer advance, and new immunotherapy combinations
Cancer Research UK. Cancer Research UK. May 29, 2026.
Summary: Cancer Research UK summarized major ASCO 2026 findings, including an oral drug showing unusual survival gains in advanced pancreatic cancer and a triple-action cancer treatment for advanced head and neck cancers. The article shows how oncology is increasingly combining targeted drugs, immune-system activation, and more precise patient selection.
Ten cancer-related breakthroughs giving us hope in 2026
Dana-Farber Cancer Institute. Dana-Farber Cancer Institute. January 20, 2026.
Summary: Dana-Farber researchers reviewed ten areas of cancer progress, including personalized cancer vaccines, CAR T-cell therapy, targeted therapies, prevention, and early detection. The article is a useful overview of where cancer science is moving: toward treatments designed around each person’s tumor biology.
FDA approvals in oncology: January-March 2026
Cancer Research Catalyst Staff. American Association for Cancer Research. April 1, 2026.
Summary: The American Association for Cancer Research summarized nine FDA oncology approvals from the first quarter of 2026. The roundup includes new treatments for blood cancers, pancreatic cancer, lung cancer, and other tumors, showing the pace at which targeted therapies, immunotherapies, and device-based cancer treatments are entering care.
AI-generated sensors open new paths for early cancer detection
Anne Trafton. MIT News. January 6, 2026.
Summary: MIT researchers used artificial intelligence to design peptide sensors that respond to cancer-linked proteases. The approach could help create urine-based or blood-based tests that detect cancer activity earlier and more broadly than traditional imaging alone, though it remains a research-stage technology.
AI blood test detects early pancreatic cancer with up to 94% accuracy
University of California San Diego. Medical Xpress. March 5, 2026.
Summary: Researchers reported an AI-assisted blood-test approach called PanMETAI that combines metabolic markers with machine learning to identify early pancreatic cancer. Because pancreatic cancer is usually found late, even experimental detection tools are closely watched for their potential to shift diagnosis toward earlier, more treatable stages.
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Andrew Gregory. The Guardian. May 30, 2026.
Summary: A large NHS trial of the Galleri multi-cancer blood test did not meet its main goal of reducing late-stage cancer diagnoses. The result is an important cautionary article for prevention because it shows that promising screening tools must prove they improve outcomes before being rolled out widely.
New blood tests promise to detect multiple cancers—but are they too good to be true?
Maggie O’Neill. Health. April 2026.
Summary: This explainer reviews multi-cancer early-detection blood tests, including their promise and their limits. It explains why a single blood draw that screens for many cancers is attractive, while also warning about false positives, uncertain benefit, lack of FDA approval for some tests, and the need to continue standard cancer screening.
FDA clears first blood test used in diagnosing Alzheimer’s disease
U.S. Food and Drug Administration. FDA. May 16, 2025.
Summary: The FDA cleared the Lumipulse blood test to help diagnose Alzheimer’s disease in adults age 55 and older who already have symptoms of cognitive decline. The test offers a less invasive way to detect amyloid-plaque biology compared with PET scans or spinal taps, but it is not intended for healthy people without symptoms.
Roche gets second European approval for Alzheimer’s test
Reuters. Reuters. May 12, 2026.
Summary: Roche received a European CE mark for another Elecsys blood test designed to help detect Alzheimer’s disease. Blood-based Alzheimer’s testing is expanding quickly because it could make diagnosis easier and cheaper, especially as treatments increasingly depend on confirming the biology behind cognitive decline.
New study: HPV and measles vaccines top vaccine impact list
Linda Geddes. Gavi VaccinesWork. May 15, 2026.
Summary: A Lancet study summarized by Gavi found that HPV and measles vaccines produced the largest impact on deaths and healthy years of life saved per 1,000 vaccinations. The finding is a public-health win because it shows how prevention through vaccination can avert both infectious disease deaths and future cancer deaths.
Malaria vaccines RTS,S and R21
World Health Organization. WHO. February 4, 2026.
Summary: WHO explains that both RTS,S and R21 malaria vaccines are safe and effective for preventing malaria in children. The vaccines are expected to have major public-health impact in malaria-endemic regions, especially when combined with bed nets, seasonal malaria prevention, testing, and treatment.
Mali pioneers novel hybrid vaccine delivery approach to combat malaria
WHO Regional Office for Africa. WHO Africa. April 25, 2025.
Summary: Mali introduced a hybrid malaria-vaccine delivery strategy that combines routine age-based doses with seasonal booster timing before peak transmission. The model is important because it adapts vaccine delivery to local malaria patterns, potentially improving protection for children during the most dangerous months.
WHO-supported mRNA vaccine technology transfer hubs pave the way for African vaccine production
WHO Regional Office for Africa. WHO Africa. April 7, 2026.
Summary: WHO Africa highlighted the role of mRNA vaccine technology transfer hubs in building vaccine-manufacturing capacity on the continent. The effort matters for prevention because local vaccine production can reduce dependence on outside suppliers and help countries respond faster to future outbreaks.
Novel drug approvals for 2026
U.S. Food and Drug Administration. FDA. Updated 2026.
Summary: The FDA’s 2026 novel-drug approval list tracks new medicines never before approved or marketed in the United States. The list is useful for monitoring medical breakthroughs across many fields, including infectious disease, anesthesia, cancer, rare disease, and chronic conditions.
Breakthrough Devices Program
U.S. Food and Drug Administration. FDA. Updated June 5, 2026.
Summary: The FDA’s Breakthrough Devices Program supports faster development and review of devices that may offer more effective treatment or diagnosis for serious diseases. The program is relevant to early detection and preventive health because many modern breakthroughs are diagnostic tools, monitoring devices, and device-drug combinations.
Nutritional strategies and aging: current evidence and future directions
S. Castelli et al. National Library of Medicine / PMC. 2026.
Summary: This review examines how nutrition may influence aging biology through metabolism, inflammation, oxidative stress, and molecular pathways linked to health span. It emphasizes that diet is not a magic anti-aging cure, but long-term nutrition patterns may affect chronic-disease risk and biological aging.
Molecular mechanisms underlying the lifespan and health benefits of dietary restriction
J. Fan et al. National Library of Medicine / PMC. 2026.
Summary: This scientific review summarizes how dietary restriction may influence longevity through pathways involving nutrient sensing, cellular repair, inflammation, and metabolism. The article is useful for separating serious longevity biology from hype, while showing why researchers continue to study fasting, calorie restriction, and diet quality.
Blood-based biomarkers for Alzheimer disease
H. E. Whitson et al. National Library of Medicine / PMC. 2026.
Summary: This review explains the rise of blood-based Alzheimer’s biomarkers and how they may change diagnosis, triage, and clinical-trial enrollment. It also stresses that test interpretation is complicated and should be connected to symptoms, clinical evaluation, and follow-up testing rather than used as a simple stand-alone answer.
Cancer Treatments and Immunotherapy
Robots improve drug tests for catching lurking cancer cells
Reuters. Reuters. June 17, 2026.
Summary: Researchers developed a robotic drug-testing platform to study rare “persister” cancer cells that survive treatment and can seed relapse. In lung-cancer experiments, the system tested dozens of drugs across thousands of cell-state variations and identified several compounds that reduced persister cells, pointing toward faster ways to find relapse-prevention strategies.
Cancer vaccines based on mRNA advance, despite US cuts
Reuters. Reuters. June 9, 2026.
Summary: mRNA cancer vaccines are moving through trials for melanoma, pancreatic cancer, brain cancer, and other tumors. The article highlights ASCO 2026 data, including longer-term melanoma results from personalized vaccine-and-immunotherapy combinations, while noting that scientists remain concerned about funding instability and political pressure around mRNA research.
Removing 'invisibility cloaks' and safely skipping chemo: new weapons in war on cancer shared at US conference
Andrew Gregory. The Guardian. June 6, 2026.
Summary: This ASCO 2026 roundup covers several cancer-treatment advances, including drugs designed to make tumors more visible to the immune system, targeted treatments for pancreatic cancer, and genomic testing that may help some breast-cancer patients avoid chemotherapy. It also emphasizes prevention, survivorship care, and global workforce shortages.
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki for HER2-positive early-stage breast cancer
U.S. Food and Drug Administration. FDA. May 16, 2026.
Summary: The FDA approved fam-trastuzumab deruxtecan-nxki, also known as Enhertu, for two uses in adults with HER2-positive early-stage breast cancer. The decision expands use of an antibody-drug conjugate into earlier breast-cancer treatment, reflecting a broader shift toward more precise therapies before metastatic disease develops.
The emerging cancer treatment that's exciting scientists: 'We've just scratched the surface on what's possible'
Donna Lu. The Guardian. May 10, 2026.
Summary: This article explains the promise and limits of CAR T-cell therapy, a treatment that engineers immune cells to recognize cancer. It describes successes in blood cancers, the challenge of solid tumors, high costs, and research into easier delivery systems that could one day make the therapy more widely available.
FDA permits expanded access for investigational pancreatic cancer drug
U.S. Food and Drug Administration. FDA. May 1, 2026.
Summary: The FDA allowed expanded access to an investigational drug for certain patients with previously treated metastatic pancreatic ductal adenocarcinoma. Expanded-access programs do not prove a drug works, but they can give patients with limited options a pathway to investigational therapy while trials continue.
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
U.S. Food and Drug Administration. FDA. February 26, 2026.
Summary: The FDA granted accelerated approval to zongertinib for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2, or ERBB2, activating mutations. The approval shows the growing importance of matching cancer drugs to specific tumor mutations using authorized diagnostic tests.
FDA approves first-of-its-kind device to treat pancreatic cancer
U.S. Food and Drug Administration. FDA. February 12, 2026.
Summary: The FDA approved Optune Pax, a portable non-invasive device that delivers tumor treating fields to the abdomen for adults with locally advanced pancreatic cancer. The device represents a new treatment category for a hard-to-treat cancer, using alternating electric fields to disrupt cancer-cell division while limiting damage to healthy tissue.
Early Detection, AI, and Preventive Screening
New AI model spots pancreatic cancer up to 3 years earlier than human doctors in test
Emily Cooke. Live Science. May 2026.
Summary: Researchers tested an AI model called REDMOD on CT scans that had previously been read as normal. The tool found subtle imaging patterns linked to later pancreatic-cancer diagnosis, suggesting that AI could help detect one of the deadliest cancers earlier, especially in high-risk patients, though clinical validation is still needed.
New research conducted using Google AI can match or exceed radiologists in detecting cancer in breast scans
Imperial College London. Imperial College London. March 10, 2026.
Summary: Researchers reported that a Google AI system could match or exceed radiologists in some breast-cancer screening tasks. The work suggests AI may eventually help reduce missed cancers, ease radiology workloads, and expand access to high-quality screening, but the technology still requires careful testing in real-world clinical settings.
Artificial Intelligence-Enabled Medical Devices
U.S. Food and Drug Administration. FDA. Updated June 16, 2026.
Summary: The FDA’s public list of AI-enabled medical devices tracks devices authorized for marketing in the United States. The list is important for preventive health because AI is increasingly used in imaging, diagnostics, risk prediction, and workflow tools, making transparency and regulatory oversight central to safe adoption.
Performance of multiple multi-cancer detection tests using a common plasma sample set
M. E. Wood et al. National Library of Medicine / PMC. 2026.
Summary: This study compares multiple multi-cancer detection tests using shared blood-plasma samples. It helps clarify how emerging blood-based cancer tests perform across cancer types, an important step before such tests can be used broadly for screening people who do not yet have symptoms.
Promise and Potential Harms of a Novel Cancer Screening Tool
C. M. Snead et al. National Library of Medicine / PMC. 2026.
Summary: This article weighs the promise of multi-cancer detection tests against risks such as false positives, overdiagnosis, anxiety, follow-up procedures, and unequal access. It is useful for understanding why early-detection tools need large trials showing not only that they find cancer, but that they improve outcomes.
Vaccines and Public-Health Wins
Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - May 2026
World Health Organization. WHO. June 9, 2026.
Summary: WHO highlighted new evidence from Ghana, Kenya, and Malawi showing that the RTS,S malaria vaccine saved child lives in early public-health use. The update frames malaria vaccination as a major child-survival tool as more countries introduce malaria vaccines into routine immunization programs.
Africa's routine vaccine systems deliver gains against cancer and malaria despite funding pressures
WHO Regional Office for Africa. WHO Africa. April 24, 2026.
Summary: WHO Africa reported that HPV vaccination has helped avert close to 1 million cervical-cancer deaths in 29 African countries, while malaria-vaccine programs are showing early impact in countries that have introduced them. The article links strong routine immunization systems to cancer prevention, child survival, and health equity.
RSV Vaccine Guidance for Adults
Centers for Disease Control and Prevention. CDC. February 24, 2026.
Summary: CDC guidance recommends a single RSV vaccine dose for all adults ages 75 and older and for adults ages 50–74 at increased risk of severe RSV illness. The recommendation reflects a growing preventive-health strategy for older adults and people with chronic conditions who face higher risks from respiratory infections.
New TB Vaccine Research
World Health Organization. WHO. 2026.
Summary: WHO summarizes the public-health and economic case for developing new tuberculosis vaccines. A more effective TB vaccine could reduce illness, death, antibiotic use, and health-system costs, making TB vaccine research one of the most important frontiers in global infectious-disease prevention.
Four in ten cancer cases could be prevented globally
World Health Organization. WHO. February 3, 2026.
Summary: WHO and the International Agency for Research on Cancer reported that up to four in ten cancer cases worldwide could be prevented. The analysis highlights preventable causes including tobacco, alcohol, high body mass index, physical inactivity, air pollution, ultraviolet radiation, and cancer-causing infections.
Nutrition, Exercise Science, and Longevity
Research Shows Just 4 Weeks of Simple Diet Changes Could Reverse Aging
Verywell Health. Verywell Health. June 2026.
Summary: This article covers a study in older adults linking short-term dietary changes to improvements in biological-age markers. The strongest signal came from a diet emphasizing complex carbohydrates, fiber, legumes, whole grains, fruits, and vegetables while limiting processed foods and saturated animal fats.
Least fit people need to do more exercise than fittest to get same benefit – study
Anna Bawden. The Guardian. May 19, 2026.
Summary: A study reported that people with the lowest fitness levels may need more additional weekly exercise than the fittest people to achieve similar cardiovascular-risk reductions. The finding complicates simple exercise messaging and suggests prevention advice may need to account for baseline fitness.
Midlife fitness linked to longer, healthier lives, study finds
Gretchen Reynolds. The Washington Post. May 17, 2026.
Summary: A long-running study linked higher midlife aerobic fitness with longer lifespan and longer health span. Participants with better treadmill-test performance in midlife tended to live longer and develop major illness later, supporting the idea that fitness is a core preventive-health investment before old age.
Study finds greater role for genetics in driving human lifespan
Will Dunham. Reuters. January 29, 2026.
Summary: A Science study suggested genetics may explain a larger share of human lifespan variation than earlier estimates, after accounting for historical causes of death such as accidents and infectious disease. The findings do not replace lifestyle prevention, but they renew interest in protective genes and biological aging mechanisms.
Five minutes more exercise and 30 minutes less sitting could help millions live longer
Andrew Gregory. The Guardian. January 13, 2026.
Summary: Researchers found that small changes in daily activity patterns, such as a few more minutes of exercise and less sedentary time, could have large population-level health benefits. The article is useful for public-health messaging because it focuses on achievable lifestyle shifts rather than extreme fitness goals.
Exercise variety—not just amount—linked to lower risk of premature mortality
Harvard T.H. Chan School of Public Health. Harvard Public Health. January 20, 2026.
Summary: Harvard researchers reported that variety in physical activity may matter for longevity, not only total exercise volume. The study suggests that combining different forms of movement could be linked to lower premature-mortality risk, adding nuance to prevention advice centered on weekly exercise minutes.
